Javascript must be enabled to continue!
Machine learning improves post-transplantation HCC recurrence prediction
View through CrossRef
We aimed to enhance post-transplantation HCC recurrence prediction by evaluating additional novel risk factors and leveraging state-of-the-art machine learning (ML) algorithms. Using the United Network for Organ Sharing (UNOS) database, we identified adult HCC patients who underwent liver transplantation (LT) 2015–2018 and considered >50 available clinical, radiographic, laboratory/biomarker, and explant pathology variables to predict post-transplantation recurrence-free survival. The cohort was split 70:30 into training and test datasets. Recursive feature elimination was employed to select an optimal number of variables for each candidate ML model. Final model performance was compared to clinically used tools with the test dataset. Of the 3106 patients identified, 7.2% developed post-transplantation HCC recurrence. The Gradient Boosting Survival algorithm performed best (C-index 0.73) and included 7 variables: explant tumor burden score (TBS), alpha fetoprotein (AFP) at transplantation, maximum pre-transplantation TBS, pre-transplantation AFP slope, microvascular invasion on explant, poor tumor differentiation on explant, and change in pre-transplantation TBS normalized by the number of locoregional therapies received. This outperformed the Risk Estimation of Tumor REcurrence After Transplant (RETREAT) Score (C-Index 0.70). A Random Survival Forest model including only preoperative variables [AFP at transplantation, pre-transplantation AFP slope, change in AFP from listing to transplantation, maximum pre-transplantation TBS, and Albumin–Bilirubin (ALBI) Grade change from listing to transplantation] was also able to predict post-LT HCC recurrence (C-Index 0.69). In summary, we developed a novel ML model that outperforms a widely used post-transplantation HCC recurrence risk score. This model may be used to better risk-stratify patients following transplantation and tailor surveillance/adjuvant therapy. The pre-transplantation ML model may be used with the Milan Criteria to further risk-stratify patients being considered for transplantation.
Ovid Technologies (Wolters Kluwer Health)
Title: Machine learning improves post-transplantation HCC recurrence prediction
Description:
We aimed to enhance post-transplantation HCC recurrence prediction by evaluating additional novel risk factors and leveraging state-of-the-art machine learning (ML) algorithms.
Using the United Network for Organ Sharing (UNOS) database, we identified adult HCC patients who underwent liver transplantation (LT) 2015–2018 and considered >50 available clinical, radiographic, laboratory/biomarker, and explant pathology variables to predict post-transplantation recurrence-free survival.
The cohort was split 70:30 into training and test datasets.
Recursive feature elimination was employed to select an optimal number of variables for each candidate ML model.
Final model performance was compared to clinically used tools with the test dataset.
Of the 3106 patients identified, 7.
2% developed post-transplantation HCC recurrence.
The Gradient Boosting Survival algorithm performed best (C-index 0.
73) and included 7 variables: explant tumor burden score (TBS), alpha fetoprotein (AFP) at transplantation, maximum pre-transplantation TBS, pre-transplantation AFP slope, microvascular invasion on explant, poor tumor differentiation on explant, and change in pre-transplantation TBS normalized by the number of locoregional therapies received.
This outperformed the Risk Estimation of Tumor REcurrence After Transplant (RETREAT) Score (C-Index 0.
70).
A Random Survival Forest model including only preoperative variables [AFP at transplantation, pre-transplantation AFP slope, change in AFP from listing to transplantation, maximum pre-transplantation TBS, and Albumin–Bilirubin (ALBI) Grade change from listing to transplantation] was also able to predict post-LT HCC recurrence (C-Index 0.
69).
In summary, we developed a novel ML model that outperforms a widely used post-transplantation HCC recurrence risk score.
This model may be used to better risk-stratify patients following transplantation and tailor surveillance/adjuvant therapy.
The pre-transplantation ML model may be used with the Milan Criteria to further risk-stratify patients being considered for transplantation.
Related Results
Hepatocellular carcinoma recurrence after liver transplant: An Australian single-centre study
Hepatocellular carcinoma recurrence after liver transplant: An Australian single-centre study
BACKGROUND
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide. Liver transplantation (LT) offers the most effective treatment. HCC recur...
Projected outcomes of 6‐month delay in exception points versus an equivalent Model for End‐Stage Liver Disease score for hepatocellular carcinoma liver transplant candidates
Projected outcomes of 6‐month delay in exception points versus an equivalent Model for End‐Stage Liver Disease score for hepatocellular carcinoma liver transplant candidates
The United Network for Organ Sharing (UNOS) recently implemented a 6‐month delay before granting exception points to liver transplantation candidates with hepatocellular carcinoma ...
Association of Genetic Polymorphisms with Clinical Characteristics and Survival of Hepatocellular Carcinoma Patients with or without Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
Association of Genetic Polymorphisms with Clinical Characteristics and Survival of Hepatocellular Carcinoma Patients with or without Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
The influence of single-nucleotide polymorphisms (SNPs) on hepatocellular carcinoma (HCC) in terms of etiological factors remains to be explored. This study evaluated the distribut...
Characterization of lymphocyte‐rich hepatocellular carcinoma and the prognostic role of tertiary lymphoid structures
Characterization of lymphocyte‐rich hepatocellular carcinoma and the prognostic role of tertiary lymphoid structures
AbstractBackground & AimsLymphocyte‐rich hepatocellular carcinoma (LR‐HCC) is largely unknown and a rare subtype of HCC with immune‐rich stroma. Tertiary lymphoid structures (T...
Pediatric Pilonidal Sinus Disease: A Single-Center Cohort Study of Clinical and Surgical Outcomes
Pediatric Pilonidal Sinus Disease: A Single-Center Cohort Study of Clinical and Surgical Outcomes
Abstract
Introduction: Pilonidal sinus disease is increasingly recognized in the pediatric population, yet evidence on its clinical characteristics and surgical outcomes in childre...
Outcomes after curative treatment for cryptogenic cirrhosis‐associated hepatocellular carcinoma satisfying the Milan criteria
Outcomes after curative treatment for cryptogenic cirrhosis‐associated hepatocellular carcinoma satisfying the Milan criteria
AbstractBackground and Aim: The prognosis of cryptogenic cirrhosis‐associated hepatocellular carcinoma (CC‐HCC) was reported to be poor because many of them were discovered at the...
Distinct alterations of gut microbiota between viral- and non-viral-related hepatocellular carcinoma
Distinct alterations of gut microbiota between viral- and non-viral-related hepatocellular carcinoma
Abstract
Altered gut microbiota has been connected to hepatocellular carcinoma (HCC) occurrence and advancement. This study was conducted to identify a gut microbiota s...
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Abstarct
Introduction
Isolated brain hydatid disease (BHD) is an extremely rare form of echinococcosis. A prompt and timely diagnosis is a crucial step in disease management. This ...

